On October 9, Kodiak Sciences Inc. rose 5.63% in regular trading, trading at $99.64 per share with Turnover of $46.97 million. The movement comes as non-executive director Felix Baker purchased $157 million in shares at $80.85 per share through affiliated fund Baker Bros. Advisors on September 29, raising the firm's stake to 35%.

The insider buying follows a dramatic single-day gain of 177.96% on September 28, when the company announced that both experimental eye drugs Zenkuda and tabirafusp-ted met primary endpoints in the DAYBREAK Phase 3 study for wet age-related macular degeneration. Smart Insider flagged the purchase as the director's largest to date, noting the acquisition was made at a higher price than his previous $60 million subscription at $23 in December 2025.

The combination of a major clinical milestone and large-scale insider accumulation has created dual fundamental and sentiment-driven support for the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)